Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over time

被引:97
作者
Medved, M
Karczmar, G
Yang, C
Dignam, J
Gajewski, TF
Kindler, H
Vokes, E
MacEneany, P
Mitchell, MT
Stadler, WM
机构
[1] Univ Chicago, Hematol Oncol Sect, Dept Med, Chicago, IL 60637 USA
[2] Univ Chicago, Dept Radiol, Chicago, IL 60637 USA
[3] Univ Chicago, Canc Res Ctr, Chicago, IL 60637 USA
[4] Univ Chicago, Dept Hlth Studies, Chicago, IL 60637 USA
关键词
pharmacodynamic marker; VEGF receptor; functional imaging; DCE-MRI; angiogenesis;
D O I
10.1002/jmri.20061
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: To evaluate variability of a simplified method for measuring semiquantitative DCE-MRI parameters in patients with cancer and to explore effects of treatment with a putative anti-angiogenic compound. Materials and Methods: A total of 19 patients enrolled on treatment trials with the putative anti-angiogenic agent SU5416 underwent contrast enhanced examinations, and 11 had a second examination eight weeks post therapy. Contrast media concentration as a function of time was calculated using changes in signal and literature baseline T, values in normal muscle or liver reference tissue. Semi-quantitative DCE-MRI parameters, including the area under the contrast concentration vs. time curve (AUC), were calculated for regions-of-interest in normal liver and muscle, and in tumors. Results: The coefficients of variation for pretherapy parameters in normal tissue were 11% to 37%. No significant changes were detected in normal liver over two months of therapy. In tumors and muscle, a significant decrease in the AUC and maximum contrast concentration was observed. Conclusion: Variability of semiquantitative DCE-MRI parameters utilizing a method based on known T, values in a reference tissue is low enough to detect changes in tumors during therapy. Use of this method as a pharmacodynamic marker should be further investigated.
引用
收藏
页码:122 / 128
页数:7
相关论文
共 26 条
[1]  
Bydder GM, 1999, Magnetic resonance imaging, V3rd, P69
[2]   Breast disease: Dynamic spiral MR imaging [J].
Daniel, BL ;
Yen, YF ;
Glover, GH ;
Ikeda, DM ;
Birdwell, RL ;
Sawyer-Glover, AM ;
Black, JW ;
Plevritis, SK ;
Jeffrey, SS ;
Herfkens, RJ .
RADIOLOGY, 1998, 209 (02) :499-509
[3]  
Evelhoch JL, 1999, JMRI-J MAGN RESON IM, V10, P254, DOI 10.1002/(SICI)1522-2586(199909)10:3<254::AID-JMRI5>3.0.CO
[4]  
2-9
[5]  
Fong TAT, 1999, CANCER RES, V59, P99
[6]   Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysis [J].
Galbraith, SM ;
Lodge, MA ;
Taylor, NJ ;
Rustin, GJS ;
Bentzen, S ;
Stirling, JJ ;
Padhani, AR .
NMR IN BIOMEDICINE, 2002, 15 (02) :132-142
[7]   Applications of magnetic resonance in model systems: Tumor biology and physiology [J].
Gillies, RJ ;
Bhujwalla, ZM ;
Evelhoch, S ;
Garwood, M ;
Neeman, M ;
Robinson, SP ;
Sotak, CH ;
Van der Sanden, B .
NEOPLASIA, 2000, 2 (1-2) :139-151
[8]   Assessing changes in tumour vascular function using dynamic contrast-enhanced magnetic resonance imaging [J].
Hayes, C ;
Padhani, AR ;
Leach, MO .
NMR IN BIOMEDICINE, 2002, 15 (02) :154-163
[9]   PHARMACOKINETIC MAPPING OF THE BREAST - A NEW METHOD FOR DYNAMIC MR MAMMOGRAPHY [J].
HOFFMANN, U ;
BRIX, G ;
KNOPP, MV ;
HESS, T ;
LORENZ, WJ .
MAGNETIC RESONANCE IN MEDICINE, 1995, 33 (04) :506-514
[10]   Assessment of coronary flow reserve:: Comparison between contrast-enhanced magnetic resonance imaging and positron emission tomography [J].
Ibrahim, T ;
Nekolla, SG ;
Schreiber, K ;
Odaka, K ;
Volz, S ;
Mehilli, J ;
Güthlin, M ;
Delius, W ;
Schwaiger, M .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (05) :864-870